Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SCOTT A FRETZIN

Allopathic & Osteopathic Physicians Dermatology

NPI
1023011244
CMS profile
91643
Location
INDIANAPOLIS, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$90,783.84

206 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 3 of 5; records 101–150 of 206 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SCOTT A FRETZIN

NPI 1023011244 · CMS profile ID 91643

Allopathic & Osteopathic Physicians / Dermatology

INDIANAPOLIS, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 5; records 101–150 of 206 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1023011244?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SCOTT A FRETZIN, NPI 1023011244, CMS profile ID 91643. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 206 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1023011244?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). SCOTT A FRETZIN, NPI 1023011244, CMS profile ID 91643. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 206 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1023011244?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
SCOTT A FRETZIN, NPI 1023011244, CMS profile ID 91643, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 5; records 101–150 of 206 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1023011244?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

206 matching records · $90,783.84 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 206 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 206.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Biotech, Inc. $9.1207/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788941821 CMS
Lilly USA, LLC $575.0007/27/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818743283 CMS
Janssen Biotech, Inc. $21.1107/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788941819 CMS
AbbVie Inc. $21.0507/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794516055 CMS
Janssen Scientific Affairs, LLC $1,013.0007/19/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788941857 CMS
Novartis Pharmaceuticals Corporation $16.0407/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812682757 CMS
Novartis Pharmaceuticals Corporation $87.9007/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812682735 CMS
Janssen Biotech, Inc. $1.0307/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788941847 CMS
Janssen Biotech, Inc. $15.2607/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788941849 CMS
UCB, Inc. $1,450.0007/07/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807421729 CMS
Novartis Pharmaceuticals Corporation $3.0806/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812682755 CMS
AbbVie Inc. $3,500.0006/29/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794516047 CMS
AbbVie Inc. $3,500.0006/29/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794516051 CMS
AbbVie Inc. $234.0806/28/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794516043 CMS
Lilly USA, LLC $4.4706/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818697535 CMS
Lilly USA, LLC $16.3106/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818725525 CMS
AbbVie Inc. $100.2406/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794516039 CMS
AbbVie Inc. $60.5806/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794516031 CMS
AbbVie Inc. $441.0006/22/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794516035 CMS
AbbVie Inc. $1.4206/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794516019 CMS
AbbVie Inc. $15.6006/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794516023 CMS
AbbVie Inc. $7.2606/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794516027 CMS
AbbVie Inc. $14.8506/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794516015 CMS
Amgen Inc. $6.1506/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826430513 CMS
AbbVie Inc. $6.2206/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794516011 CMS
Amgen Inc. $15.4906/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826430509 CMS
Lilly USA, LLC $1,150.0006/14/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818698849 CMS
E.R. Squibb & Sons, L.L.C. $1,250.0006/11/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783652045 CMS
AbbVie Inc. $10.6706/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794516007 CMS
UCB, Inc. $1,450.0006/07/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807357641 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $1,600.0006/02/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851927973 CMS
UCB, Inc. $2,360.0006/01/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807426275 CMS
Amgen Inc. $3,000.0005/27/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826430517 CMS
Novartis Pharmaceuticals Corporation $3.0205/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812682753 CMS
AbbVie Inc. $14.7105/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794516003 CMS
Janssen Biotech, Inc. $6.1305/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788941825 CMS
Lilly USA, LLC $16.8805/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818753029 CMS
AbbVie Inc. $20.7105/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794515999 CMS
Amgen Inc. $123.6105/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826430521 CMS
AbbVie Inc. $14.2705/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794515995 CMS
Amgen Inc. $1,250.0005/17/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826430497 CMS
Janssen Scientific Affairs, LLC $1,350.0005/15/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788941855 CMS
AbbVie Inc. $12.6005/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794515991 CMS
Lilly USA, LLC $1,150.0005/11/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818725523 CMS
AbbVie Inc. $9.0305/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794515987 CMS
PFIZER INC. $20.5505/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832566323 CMS
Novartis Pharmaceuticals Corporation $10.4605/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812682747 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $81.7205/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851927975 CMS
Novartis Pharmaceuticals Corporation $6.8005/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812682749 CMS
UCB, Inc. $2,000.0005/04/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807398823 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $183,083.92 308
PY2020 $64,066.23 155
PY2021 $90,783.84 206
PY2022 $127,366.81 266
PY2023 $128,149.76 278
PY2024 $92,536.31 239
PY2025 $108,481.42 268

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,638.02 8
PY2025 Principal investigator $1,302,291.15 229
PY2024 Recipient $114.46 1
PY2024 Principal investigator $1,170,043.67 187
PY2023 Recipient $4,895.67 2
PY2023 Principal investigator $830,146.44 133
PY2022 Recipient $194.00 1
PY2022 Principal investigator $1,120,785.72 168
PY2021 Principal investigator $1,483,673.50 196
PY2020 Recipient $3,573.00 4
PY2020 Principal investigator $1,365,446.43 248
PY2019 Recipient $32,006.00 3
PY2019 Principal investigator $1,747,506.82 173

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

237 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $3,537.36 12/31/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH
A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, and Tolerability of Upadacitinib in Adult and Adolescent Subjects with Non-Segmental Vitiligo Who Are Eligible for Systemic Therapy No dispute reported 06/30/2026 1202534141
Principal investigator 1 PFIZER INC. $11,035.00 12/31/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Group LLC
A PHASE 3 MULTICENTER LONGTERM OPEN LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO PEDIATRIC PARTICIPANTS AGED 2 YEARS AND OLDER WITH MODERATETOSEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228738482
Principal investigator 1 PFIZER INC. $2,408.27 12/31/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Group LLC
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228745037
Principal investigator 1 PFIZER INC. $5,000.00 12/31/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Group LLC
PHASE 1 PKPD STUDY 6 TO 12 A STUDY TO DETERMINE THE SAFETY AND TOLERABILITY OF JAK1 IN PATIENTS AGED 6 TO 12 No dispute reported 06/30/2026 1228747936
Principal investigator 1 PFIZER INC. $13,809.00 12/31/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Group LLC
A PHASE 2 MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 16WEEK STUDY EVALUATING THE SAFETY AND EFFICACY OF RITLECITINIB PF06651600 IN ADULTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 1228750370
Principal investigator 1 Janssen Research & Development, LLC $13,726.00 12/29/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCHGROU
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1175305794
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $25.24 12/18/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220799145
Principal investigator 1 Boehringer Ingelheim International GmbH $19.92 12/17/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220679160
Principal investigator 1 Boehringer Ingelheim International GmbH $163.24 12/17/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220679162
Principal investigator 1 Boehringer Ingelheim International GmbH $159.84 12/17/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220679164
Principal investigator 1 Boehringer Ingelheim International GmbH $1,241.00 12/17/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220679166
Principal investigator 1 Boehringer Ingelheim International GmbH $21.60 12/17/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220679168
Principal investigator 1 Boehringer Ingelheim International GmbH $305.90 12/17/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220679170
Principal investigator 1 Boehringer Ingelheim International GmbH $25.35 12/17/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220679172
Principal investigator 1 Boehringer Ingelheim International GmbH $25.35 12/17/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220679174
Principal investigator 1 Boehringer Ingelheim International GmbH $25.35 12/17/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220679176
Principal investigator 1 Boehringer Ingelheim International GmbH $25.35 12/17/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220679178
Principal investigator 1 Boehringer Ingelheim International GmbH $58.62 12/17/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220679180
Principal investigator 1 Boehringer Ingelheim International GmbH $35.76 12/17/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220679182
Principal investigator 1 Boehringer Ingelheim International GmbH $258.06 12/17/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220679184
Principal investigator 1 Boehringer Ingelheim International GmbH $41.50 12/17/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220679186
Principal investigator 1 PFIZER INC. $1,876.50 12/17/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Group LLC
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228723886
Principal investigator 1 PFIZER INC. $5,000.00 12/16/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Group LLC
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228745064
Principal investigator 1 PFIZER INC. $1,114.76 12/11/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Group LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RITLECITINIB IN PEDIATRIC PARTICIPANTS 6 TO LESS THAN 12 YEARS OF AGE WITH SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 1228732247
Principal investigator 1 SANOFI US SERVICES INC. $8,377.00 12/08/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Gro LLC
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226113774
Principal investigator 1 ABBVIE INC. $4,482.00 12/04/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202526702
Principal investigator 1 ABBVIE INC. $5,833.50 12/04/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202526704
Principal investigator 1 ABBVIE INC. $10,634.25 12/04/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202526706
Principal investigator 1 Hoffmann-La Roche Limited $1,511.00 12/01/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Group, LLC
VELARITE No dispute reported 06/30/2026 1211595724
Principal investigator 1 Hoffmann-La Roche Limited $1,658.00 12/01/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Group, LLC
VELARITE No dispute reported 06/30/2026 1211595729
Principal investigator 1 PFIZER INC. $4,462.43 11/26/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Group LLC
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228729574
Principal investigator 1 PFIZER INC. $2,408.27 11/25/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Group LLC
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228729412
Principal investigator 1 PFIZER INC. $4,814.75 11/25/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Group LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RITLECITINIB IN PEDIATRIC PARTICIPANTS 6 TO LESS THAN 12 YEARS OF AGE WITH SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 1228737694
Principal investigator 1 Boehringer Ingelheim International GmbH $20.88 11/19/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220679158
Principal investigator 1 ABBVIE INC. $16,346.25 11/05/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202522791
Principal investigator 1 ABBVIE INC. $20,361.60 11/05/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202522793
Principal investigator 1 ABBVIE INC. $3,463.50 11/05/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202522859
Principal investigator 1 SANOFI US SERVICES INC. $510.60 11/05/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Gro LLC
Registry to characterize the patients who receive Dupixent for PN in a real-world setting No dispute reported 06/30/2026 1226113791
Principal investigator 1 ABBVIE INC. $6,201.60 11/04/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202521023
Principal investigator 1 ABBVIE INC. $14,451.75 11/04/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202521025
Principal investigator 1 Hoffmann-La Roche Limited $2,371.00 11/03/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Group, LLC
VELARITE No dispute reported 06/30/2026 1211595716
Principal investigator 1 Hoffmann-La Roche Limited $1,981.00 11/03/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Group, LLC
VELARITE No dispute reported 06/30/2026 1211595720
Principal investigator 1 Janssen Research & Development, LLC $16,246.00 11/03/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCHGROU
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1175305801
Principal investigator 1 SANOFI US SERVICES INC. $14,857.00 10/20/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Gro LLC
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226113719
Principal investigator 1 SANOFI US SERVICES INC. $2,397.60 10/17/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Gro LLC
Registry to characterize the patients who receive Dupixent for PN in a real-world setting No dispute reported 06/30/2026 1226113782
Principal investigator 1 Eli Lilly and Company $1,083.00 10/10/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 1187878713
Principal investigator 1 ABBVIE INC. $2,571.95 10/09/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202513901
Principal investigator 1 ABBVIE INC. $28,536.30 10/09/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202513903
Principal investigator 1 PFIZER INC. $1,233.63 10/09/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Group LLC
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228741580
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,220.80 10/08/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research
Randomised, double-blind, placebo-controlled, Phase IIb/Phase III study to evaluate the efficacy and safety of spesolimab in patients with moderate to severe hidradenitis suppurativa. Lunsayil 1. No dispute reported 06/30/2026 1220791510
Principal investigator 1 PFIZER INC. $4,069.42 10/03/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Group LLC
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228722858
Principal investigator 1 Janssen Research & Development, LLC $14,853.00 09/29/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCHGROU P LLC
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1175305749
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 09/25/2025 Non-covered Recipient Entity
Dawes Fretzin Clinic Rsrch
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175216988
Principal investigator 1 Boehringer Ingelheim International GmbH $11.66 09/24/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220679152
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 09/24/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220679154
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 09/24/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220679156
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,500.00 09/24/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research
Randomised, double-blind, placebo-controlled, Phase IIb/Phase III study to evaluate the efficacy and safety of spesolimab in patients with moderate to severe hidradenitis suppurativa. Lunsayil 1. No dispute reported 06/30/2026 1220791508
Principal investigator 1 PFIZER INC. $1,098.63 09/24/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Group LLC
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228750508
Principal investigator 1 PFIZER INC. $10,240.00 09/24/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Group LLC
A LONGTERM DOUBLEBLIND EXTENSION STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF RITLECITINIB IN PARTICIPANTS WITH SEVERE ALOPECIA AREATA WHO PREVIOUSLY COMPLETED STUDIES B7981027 OR B7981031 No dispute reported 06/30/2026 1228770443
Principal investigator 1 ABBVIE INC. $3,321.00 09/09/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202510324
Principal investigator 1 PFIZER INC. $13,640.00 09/09/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Group LLC
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228757496
Principal investigator 1 ABBVIE INC. $10,162.20 09/03/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202507637
Principal investigator 1 ABBVIE INC. $1,458.50 09/03/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202507639
Principal investigator 1 SANOFI US SERVICES INC. $8,179.00 09/03/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Gro LLC
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226113715
Principal investigator 1 PFIZER INC. $1,661.15 08/30/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Group LLC
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228766623
Principal investigator 1 Janssen Research & Development, LLC $16,371.00 08/29/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCHGROU P LLC
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1175305740
Principal investigator 1 Boehringer Ingelheim International GmbH $23.32 08/26/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220679132
Principal investigator 1 Boehringer Ingelheim International GmbH $292.00 08/26/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220679134
Principal investigator 1 Boehringer Ingelheim International GmbH $4.80 08/26/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220679136
Principal investigator 1 Boehringer Ingelheim International GmbH $87.40 08/26/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220679138
Principal investigator 1 Boehringer Ingelheim International GmbH $25.35 08/26/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220679140
Principal investigator 1 Boehringer Ingelheim International GmbH $25.35 08/26/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220679142
Principal investigator 1 Boehringer Ingelheim International GmbH $25.35 08/26/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220679144
Principal investigator 1 Boehringer Ingelheim International GmbH $25.35 08/26/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220679146
Principal investigator 1 Boehringer Ingelheim International GmbH $46.92 08/26/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220679148
Principal investigator 1 Boehringer Ingelheim International GmbH $11.00 08/26/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220679150
Principal investigator 1 PFIZER INC. $2,095.07 08/20/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Group LLC
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228767570
Principal investigator 1 SANOFI US SERVICES INC. $5,856.30 08/20/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Gro LLC
A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226113735
Principal investigator 1 Janssen Research & Development, LLC $670.00 08/19/2025 Non-covered Recipient Entity
Dawes Fretzin Clinic Rsrch
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175216878
Principal investigator 1 Janssen Research & Development, LLC $1,978.00 08/19/2025 Non-covered Recipient Entity
Dawes Fretzin Clinic Rsrch
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175217240
Principal investigator 1 PFIZER INC. $4,620.00 08/14/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Group LLC
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228787438
Principal investigator 1 Janssen Research & Development, LLC $23,998.00 08/08/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCHGROU P LLC
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1175305785
Principal investigator 1 ABBVIE INC. $3,668.00 08/06/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202502949
Principal investigator 1 SANOFI US SERVICES INC. $3,480.30 08/06/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Gro LLC
A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226113731
Principal investigator 1 SANOFI US SERVICES INC. $1,024.65 08/06/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Gro LLC
A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226113746
Principal investigator 1 SANOFI US SERVICES INC. $4,500.00 08/06/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Gro LLC
A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226113758
Principal investigator 1 SANOFI US SERVICES INC. $1,250.00 08/06/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Gro LLC
A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226113764
Principal investigator 1 SANOFI US SERVICES INC. $1,500.00 08/06/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Gro LLC
A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226113771
Principal investigator 1 ABBVIE INC. $1,458.50 08/05/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202501616
Principal investigator 1 PFIZER INC. $2,694.74 08/05/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Group LLC
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228767102
Principal investigator 1 SANOFI US SERVICES INC. $4,668.00 08/04/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Gro LLC
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226113685
Principal investigator 1 SANOFI US SERVICES INC. $12,904.00 08/04/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Gro LLC
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226113688
Principal investigator 1 PFIZER INC. $10,040.00 08/02/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Group LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RITLECITINIB IN PEDIATRIC PARTICIPANTS 6 TO LESS THAN 12 YEARS OF AGE WITH SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 1228785701
Principal investigator 1 Eli Lilly and Company $31,644.00 07/28/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A PHASE 4, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH ATOPIC DERMATITIS WITH LIMITED BODY SURFACE AREA INVOLVEMENT AND HIGH ITCH BURDEN (ADSOLVE) No dispute reported 06/30/2026 1187879713
Principal investigator 1 Hoffmann-La Roche Limited $7,793.00 07/25/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Group, LLC
VELARITE No dispute reported 06/30/2026 1211595699
Principal investigator 1 Hoffmann-La Roche Limited $1,700.00 07/25/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Group, LLC
VELARITE No dispute reported 06/30/2026 1211595704
Principal investigator 1 Hoffmann-La Roche Limited $200.00 07/25/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Group, LLC
VELARITE No dispute reported 06/30/2026 1211595708
Principal investigator 1 Hoffmann-La Roche Limited $750.00 07/25/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Group, LLC
VELARITE No dispute reported 06/30/2026 1211595712
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,004.00 07/24/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research
Randomised, double-blind, placebo-controlled, Phase IIb/Phase III study to evaluate the efficacy and safety of spesolimab in patients with moderate to severe hidradenitis suppurativa. Lunsayil 1. No dispute reported 06/30/2026 1220791506
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $10,700.00 07/23/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220791500
Principal investigator 1 Eli Lilly and Company $3,083.11 07/17/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A PHASE 4, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH ATOPIC DERMATITIS WITH LIMITED BODY SURFACE AREA INVOLVEMENT AND HIGH ITCH BURDEN (ADSOLVE) No dispute reported 06/30/2026 1187879789
Principal investigator 1 SANOFI US SERVICES INC. $9,235.00 07/14/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Gro LLC
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226113676
Principal investigator 1 SANOFI US SERVICES INC. $12,500.00 07/14/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Gro LLC
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226113680
Principal investigator 1 PFIZER INC. $2,026.89 07/11/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Group LLC
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228787110
Principal investigator 1 Janssen Research & Development, LLC $19,492.00 07/10/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCHGROU P LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175305757
Principal investigator 1 SANOFI US SERVICES INC. $1,500.00 07/09/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Gro LLC
Registry to characterize the patients who receive Dupixent for PN in a real-world setting No dispute reported 06/30/2026 1226113751
Principal investigator 1 ABBVIE INC. $1,799.25 07/08/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202497468
Principal investigator 1 Galderma Laboratories, L.P. $1,000.00 07/07/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL
A Multicenter, Open-Label, Single-Group Clinical Trial to Assess the Pharmacokinetics, Safety and Efficacy of Nemolizumab (CD14152) in Pediatric Subjects (aged 2 to 11 years) with Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 1234515136
Principal investigator 1 Galderma Laboratories, L.P. $1,000.00 07/07/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL
A Multicenter, Open-Label, Single-Group Clinical Trial to Assess the Pharmacokinetics, Safety and Efficacy of Nemolizumab (CD14152) in Pediatric Subjects (aged 2 to 11 years) with Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 1234515139
Principal investigator 1 Galderma Laboratories, L.P. $199.00 07/07/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL
A Multicenter, Open-Label, Single-Group Clinical Trial to Assess the Pharmacokinetics, Safety and Efficacy of Nemolizumab (CD14152) in Pediatric Subjects (aged 2 to 11 years) with Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 1234515152
Principal investigator 1 ABBVIE INC. $8,423.85 07/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202496491
Principal investigator 1 ABBVIE INC. $9,721.20 07/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202496493
Principal investigator 1 ABBVIE INC. $2,165.50 07/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202496589
Principal investigator 1 ABBVIE INC. $13,226.10 07/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202496591
Principal investigator 1 SANOFI US SERVICES INC. $8,518.60 07/02/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Gro LLC
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226113667
Principal investigator 1 SANOFI US SERVICES INC. $14,131.80 07/02/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Gro LLC
A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226113741
Principal investigator 1 Janssen Research & Development, LLC $15,345.00 06/30/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCHGROU P LLC
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1175305772
Principal investigator 1 UCB SA $2,145.00 06/30/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research
A MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY TO ASSESS THE PHARMACOKINETICS, SAFETY, AND EFFICACY OF TWO DOSES OF BIMEKIZUMAB IN ADOLESCENT STUDY PARTICIPANTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS No dispute reported 06/30/2026 1246657834
Principal investigator 1 PFIZER INC. $3,447.37 06/26/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Group LLC
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228776218
Principal investigator 1 PFIZER INC. $1,328.51 06/26/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Group LLC
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228778147
Principal investigator 1 PFIZER INC. $11,235.00 06/26/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Group LLC
PHASE 1 PKPD STUDY 6 TO 12 A STUDY TO DETERMINE THE SAFETY AND TOLERABILITY OF JAK1 IN PATIENTS AGED 6 TO 12 No dispute reported 06/30/2026 1228786895
Principal investigator 1 SANOFI US SERVICES INC. $36,213.75 06/11/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Gro LLC
A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226113706
Principal investigator 1 ABBVIE INC. $1,360.50 06/03/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202487333
Principal investigator 1 ABBVIE INC. $2,201.30 06/03/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH
A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy No dispute reported 06/30/2026 1202487441
Principal investigator 1 ABBVIE INC. $1,990.00 06/03/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202488227
Principal investigator 1 ABBVIE INC. $3,994.05 06/03/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202489577
Principal investigator 1 ABBVIE INC. $7,738.65 06/03/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202489679
Principal investigator 1 ABBVIE INC. $5,243.10 06/03/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202489785
Principal investigator 1 Eli Lilly and Company $13,649.95 06/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC HAND AND FOOT DERMATITIS No dispute reported 06/30/2026 1187878711
Principal investigator 1 Janssen Research & Development, LLC $23,391.00 06/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCHGROU P LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1175305733
Principal investigator 1 PFIZER INC. $2,695.00 05/30/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Group LLC
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228764508
Principal investigator 1 ABBVIE INC. $1,592.00 05/29/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH
A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (Level Up) No dispute reported 06/30/2026 1202487039
Principal investigator 1 PFIZER INC. $1,596.11 05/29/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Group LLC
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228764412
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 05/27/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220679122
Principal investigator 1 Boehringer Ingelheim International GmbH $7.20 05/27/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220679124
Principal investigator 1 Boehringer Ingelheim International GmbH $65.55 05/27/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220679126
Principal investigator 1 Boehringer Ingelheim International GmbH $70.38 05/27/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220679128
Principal investigator 1 Boehringer Ingelheim International GmbH $10.50 05/27/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220679130
Principal investigator 1 SANOFI US SERVICES INC. $8,118.10 05/27/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Gro LLC
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226113660
Principal investigator 1 ABBVIE INC. $18,629.84 05/15/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH
A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (Level Up) No dispute reported 06/30/2026 1202485163
Principal investigator 1 PFIZER INC. $2,989.66 05/14/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Group LLC
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228772743
Principal investigator 1 ABBVIE INC. $1,799.25 05/07/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202483753
Principal investigator 1 ABBVIE INC. $1,794.55 05/07/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202483755
Principal investigator 1 ABBVIE INC. $1,875.25 05/07/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202483757
Principal investigator 1 ABBVIE INC. $1,421.25 05/07/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202483759
Principal investigator 1 ABBVIE INC. $6,097.05 05/07/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202483887
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,494.00 05/07/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research
Randomised, double-blind, placebo-controlled, Phase IIb/Phase III study to evaluate the efficacy and safety of spesolimab in patients with moderate to severe hidradenitis suppurativa. Lunsayil 1. No dispute reported 06/30/2026 1220791504
Principal investigator 1 SANOFI US SERVICES INC. $440.40 05/07/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Gro LLC
Registry to characterize the patients who receive Dupixent for PN in a real-world setting No dispute reported 06/30/2026 1226113700
Principal investigator 1 ABBVIE INC. $1,448.25 05/06/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202482143
Principal investigator 1 PFIZER INC. $2,577.82 05/06/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Group LLC
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228722770
Principal investigator 1 PFIZER INC. $5,648.56 05/06/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Group LLC
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228764501
Principal investigator 1 Incyte Corporation $3,993.06 04/24/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS) No dispute reported 06/30/2026 1240522673
Principal investigator 1 Eli Lilly and Company $6,714.77 04/23/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC HAND AND FOOT DERMATITIS No dispute reported 06/30/2026 1187879711
Principal investigator 1 Eli Lilly and Company $6,915.00 04/22/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEKIZUMAB IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT IN CLINICAL PRACTICE No dispute reported 06/30/2026 1187880699
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $31.11 04/15/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220799143
Principal investigator 1 SANOFI US SERVICES INC. $8,690.65 04/14/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Gro LLC
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226113640
Principal investigator 1 Janssen Research & Development, LLC $8,900.00 04/11/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCHGROU P LLC
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1175305766
Principal investigator 1 SANOFI US SERVICES INC. $2,585.25 04/11/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Gro LLC
Registry to characterize the patients who receive Dupixent for PN in a real-world setting No dispute reported 06/30/2026 1226113693
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $20,108.60 04/10/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research
A Phase 3B/4, Multicenter, Randomized, Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Moderate-to-severe Scalp Psoriasis (PSORIATYK SCALP) No dispute reported 06/30/2026 1235997760
Principal investigator 1 Eli Lilly and Company $21,747.10 04/10/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1187880753
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $7,626.75 04/09/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Group, Llc
A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis No dispute reported 06/30/2026 1235997758
Principal investigator 1 PFIZER INC. $1,596.11 04/08/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Group LLC
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228797888
Principal investigator 1 ABBVIE INC. $5,868.90 04/03/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202468800
Principal investigator 1 ABBVIE INC. $1,956.25 04/03/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202468805
Principal investigator 1 ABBVIE INC. $526.00 04/03/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH
A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (Level Up) No dispute reported 06/30/2026 1202468809
Principal investigator 1 ABBVIE INC. $8,061.00 04/03/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202468813
Principal investigator 1 ABBVIE INC. $3,531.00 04/03/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202468822
Principal investigator 1 ABBVIE INC. $1,215.30 04/03/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH
A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy No dispute reported 06/30/2026 1202473950
Principal investigator 1 Janssen Research & Development, LLC $2,754.00 03/31/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCHGROU P LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175305780
Principal investigator 1 SANOFI US SERVICES INC. $7,864.45 03/24/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Gro LLC
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226113637
Principal investigator 1 UCB SA $46,191.00 03/21/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research
A MULTICENTER, RANDOMIZED, PARALLEL-GROUP, DOUBLE-BLIND, ACTIVE-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIMEKIZUMAB COMPARED TO USTEKINUMAB IN CHILDREN AND ADOLESCENTS FROM 6 YEARS TO LESS THAN 18 YEARS OF AGE WITH MODERATE TO SEVERE PLAQUE PSORIASIS No dispute reported 06/30/2026 1246656310
Principal investigator 1 PFIZER INC. $1,131.83 03/14/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Group LLC
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228789307
Principal investigator 1 ABBVIE INC. $8,267.60 03/07/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH
M17-380 - A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202459289
Principal investigator 1 ABBVIE INC. $1,360.50 03/07/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202459293
Principal investigator 1 ABBVIE INC. $2,613.30 03/07/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202459298
Principal investigator 1 ABBVIE INC. $5,006.25 03/07/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH
M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202460293
Principal investigator 1 ABBVIE INC. $3,624.20 03/07/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH
M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202460743
Principal investigator 1 ABBVIE INC. $1,299.75 03/06/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202456521
Principal investigator 1 Incyte Corporation $825.66 03/05/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS) No dispute reported 06/30/2026 1240522669
Principal investigator 1 ABBVIE INC. $3,030.60 03/04/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy No dispute reported 06/30/2026 1202455575
Principal investigator 1 PFIZER INC. $1,249.31 03/04/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Group LLC
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228781149
Principal investigator 1 Janssen Research & Development, LLC $3,021.00 03/03/2025 Non-covered Recipient Entity
Dawes Fretzin Clinic Rsrch
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175216955
Principal investigator 1 PFIZER INC. $3,781.09 02/28/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Group LLC
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228758719
Principal investigator 1 SANOFI US SERVICES INC. $9,745.55 02/24/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Gro LLC
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226113629
Recipient Regeneron Pharmaceuticals, Inc. $56.00 02/21/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184117597
Principal investigator 1 Janssen Research & Development, LLC $1,386.00 02/18/2025 Non-covered Recipient Entity
Dawes Fretzin Clinic Rsrch
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175216928
Principal investigator 1 PFIZER INC. $8,950.00 02/11/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Group LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228757463
Recipient Regeneron Pharmaceuticals, Inc. $325.47 02/07/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184117585
Recipient Regeneron Pharmaceuticals, Inc. $446.00 02/07/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184117587
Recipient Regeneron Pharmaceuticals, Inc. $68.89 02/07/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184117589
Recipient Regeneron Pharmaceuticals, Inc. $30.01 02/07/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184117591
Recipient Regeneron Pharmaceuticals, Inc. $96.17 02/07/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184117593
Recipient Regeneron Pharmaceuticals, Inc. $62.01 02/07/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184117595
Principal investigator 1 ABBVIE INC. $1,630.50 02/06/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202446858
Principal investigator 1 ABBVIE INC. $11,271.00 02/06/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH
M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202447382
Principal investigator 1 ABBVIE INC. $1,423.40 02/06/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH
M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202447387
Principal investigator 1 ABBVIE INC. $100.00 02/06/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH
M17-380 - A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202447525
Principal investigator 1 Incyte Corporation $370.32 02/06/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 1240522660
Principal investigator 1 PFIZER INC. $1,563.80 02/06/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Group LLC
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228759310
Principal investigator 1 ABBVIE INC. $4,222.50 02/05/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202444447
Principal investigator 1 Amgen Inc. $11,991.72 02/05/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP, LLC
A Phase 3, Multi-center, Open-label, Single-arm Study to Assess the Safety of Apremilast (AMG 407) in Pediatric Participants From 6 Through 17 Years of Age With Mild to Moderate Plaque Psoriasis No dispute reported 06/30/2026 1246640655
Principal investigator 1 Eli Lilly and Company $25,587.60 02/05/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
AN OPEN-LABEL, STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS PREVIOUSLY TREATED WITH DUPILUMAB No dispute reported 06/30/2026 1187878709
Principal investigator 1 SANOFI US SERVICES INC. $16,265.25 02/04/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Gro LLC
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226113625
Principal investigator 1 Boehringer Ingelheim International GmbH $7,440.40 01/30/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220679092
Principal investigator 1 Amgen Inc. $21,099.65 01/27/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP, LLC
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) No dispute reported 06/30/2026 1246640653
Principal investigator 1 Boehringer Ingelheim International GmbH $6.64 01/27/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220679094
Principal investigator 1 Boehringer Ingelheim International GmbH $46.64 01/27/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220679096
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 01/27/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220679098
Principal investigator 1 Boehringer Ingelheim International GmbH $474.50 01/27/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220679100
Principal investigator 1 Boehringer Ingelheim International GmbH $4.80 01/27/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220679102
Principal investigator 1 Boehringer Ingelheim International GmbH $87.40 01/27/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220679104
Principal investigator 1 Boehringer Ingelheim International GmbH $30.42 01/27/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220679106
Principal investigator 1 Boehringer Ingelheim International GmbH $30.42 01/27/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220679108
Principal investigator 1 Boehringer Ingelheim International GmbH $30.42 01/27/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220679110
Principal investigator 1 Boehringer Ingelheim International GmbH $30.42 01/27/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220679112
Principal investigator 1 Boehringer Ingelheim International GmbH $19.54 01/27/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220679114
Principal investigator 1 Boehringer Ingelheim International GmbH $23.84 01/27/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220679116
Principal investigator 1 Boehringer Ingelheim International GmbH $62.56 01/27/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220679118
Principal investigator 1 Boehringer Ingelheim International GmbH $11.00 01/27/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220679120
Principal investigator 1 Eli Lilly and Company $5,584.56 01/27/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187881254
Principal investigator 1 PFIZER INC. $1,279.80 01/24/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Group LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228713820
Principal investigator 1 PFIZER INC. $2,257.20 01/24/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Group LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228714014
Principal investigator 1 PFIZER INC. $2,611.22 01/24/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Group LLC
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228799726
Principal investigator 1 SANOFI US SERVICES INC. $610.60 01/24/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Gro LLC
Registry to characterize the patients who receive Dupixent for PN in a real-world setting No dispute reported 06/30/2026 1226113648
Principal investigator 1 Incyte Corporation $3,289.87 01/23/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 1240522656
Principal investigator 1 ABBVIE INC. $5,000.00 01/21/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH
M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202440364
Recipient Regeneron Pharmaceuticals, Inc. $553.47 01/21/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184117583
Principal investigator 1 PFIZER INC. $2,672.50 01/15/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Group LLC
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228799375
Principal investigator 1 SANOFI US SERVICES INC. $769.50 01/15/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Gro LLC
Registry to characterize the patients who receive Dupixent for PN in a real-world setting No dispute reported 06/30/2026 1226113654
Principal investigator 1 ABBVIE INC. $2,430.60 01/09/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy No dispute reported 06/30/2026 1202437349
Principal investigator 1 Eli Lilly and Company $58,791.07 01/08/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A PHASE 2B, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE ELTREKIBART IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 1187877829
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,789.90 01/07/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research
Randomised, double-blind, placebo-controlled, Phase IIb/Phase III study to evaluate the efficacy and safety of spesolimab in patients with moderate to severe hidradenitis suppurativa. Lunsayil 1. No dispute reported 06/30/2026 1220791502
Principal investigator 1 Eli Lilly and Company $94,073.00 01/07/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187881332
Principal investigator 1 Incyte Corporation $2,194.24 01/04/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS) No dispute reported 06/30/2026 1240522664
Principal investigator 1 ABBVIE INC. $2,829.00 01/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202433454
Principal investigator 1 ABBVIE INC. $481.15 01/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH
M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202433485
Principal investigator 1 Amgen Inc. $14,321.51 01/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP, LLC
P2 Moderate-Severe pDLE No dispute reported 06/30/2026 1246640657